Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics: Chief Commercial Officer Nicholas Grund to resign effective Nov. 6

Neutral Impact 3 of 5 leadership Written later

Akebia Therapeutics said its Senior Vice President and Chief Commercial Officer, Nicholas Grund, will resign effective November 6, 2026, for personal reasons. Under a consulting agreement, he will advise the company until April 30, 2027, and be paid an hourly rate.

Key points

  • Nicholas Grund notified the company of his resignation on October 7, 2026.
  • Resignation takes effect November 6, 2026.
  • Consulting Period runs until April 30, 2027; either side can end it early with notice (10 days for the company, 30 days for Mr. Grund).
  • The filing does not state a replacement for the chief commercial officer role.

The filing

CompanyAkebia Therapeutics, Inc. (AKBA)
Form8-K, current report
Filed with the SECOct 14, 2026, 7:57 AM ET
Accession number0001517022-26-000071

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.